Business
United States Epilepsy Drugs Market Trends and Company Analysis Report 2025-2033 Featuring Eisai, UCB, H. Lundbeck, GW Pharmaceuticals, Abbott, Alkem Laboratories, Bausch Health, GSK
The United States Epilepsy Drugs Market is projected to grow from US$ 2.36 billion in 2024 to US$ 3.45 billion by 2033, marking a CAGR of 4.31% from 2025 to 2033. This growth is fueled by the rising prevalence of epilepsy, affecting over 3.4 million Americans, and advancements in drug development. Key players like Eisai, UCB, and Lundbeck emphasize second and third-generation AEDs offering improved safety and efficacy. Despite challenges like high treatment costs and regulatory hurdles, the mark
About this update from Bausch Health Companies Inc.
[{"type":"image","alt":"Company Logo","displaySize":"","headline":null,"caption":"Company Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":36,"url":"https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/g_3H8YP5.WdAX5cBtX03VA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65","width":300,"height":36}},"lazy":false},{"type":"text","content":"The United States Epilepsy Drugs Market is projected to grow from US$ 2.36 billion in 2024 to US$ 3.45 billion by 2033, marking a CAGR of 4.31% from 2025 to 2033. This growth is fueled by the rising prevalence of epilepsy, affecting over 3.4 million Americans, and advancements in drug development. Key players like Eisai, UCB, and Lundbeck emphasize second and third-generation AEDs offering improved safety and efficacy. Despite challenges like high treatment costs and regulatory hurdles, the market benefits from supportive FDA policies. Segmentation includes first, second, and third-generation drugs across various seizures and distribution channels.","length":656,"tagName":"p"},{"type":"text","content":"U.S. Epilepsy Drugs Market","length":26,"tagName":"p"},{"type":"image","alt":"U.S. Epilepsy Drugs Market","displaySize":"","headline":null,"caption":"U.S. Epilepsy Drugs Market","credit":"GlobeNewswire Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":600,"height":400,"url":"https://media.zenfs.com/en/globenewswire.com/88f4efaaab5c4511d79ade3b7dce3b4e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/4dwK0m9DjWfNTMi6UB7oiQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/88f4efaaab5c4511d79ade3b7dce3b4e","width":600,"height":400}}},{"type":"text","content":"Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The "United States Epilepsy Drugs Market - Therapeutic Landscape & Forecast 2025-2033" report has been added to ResearchAndMarkets.com's offering.United States Epilepsy Drugs Market is expected to reach US$ 3.45 billion by 2033 from US$ 2.36 billion in 2024, with a CAGR of 4.31% from 2025 to 2033","length":360,"tagName":"p"},{"type":"text","content":"In order to satisfy shifting customer needs, firms are being prompted by this transition ...